{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-26-000101","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2026-09-16T20:05:40+00:00","discovered_at":"2026-09-16T20:07:10.465540+00:00","generated_at":"2026-09-16T20:07:31.841812+00:00","sec_items":["5.02","1.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Gossamer Bio appoints Greg Ciongoli to board, Audit Committee","bullets":["Ciongoli, Class III director effective Sept 16, 2026, term to 2027 annual meeting; joins Audit Committee.","Founder/managing partner of Adiumentum Capital (since 2024); ex-Baupost Group partner; also on REGENXBIO, Zymeworks, Atara boards.","He participated in Aug 2026 PIPE: pre-funded warrants for ~22,337 common (initial), ~111,687 (second closing), ~66,845 (FDA approval) post-approval.","Annual cash retainers: $40,000 board, $7,500 audit; standard equity award amount set at future board discretion."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-26-000101","json":"https://secwatch.observer/filing/0001728117-26-000101.json","markdown":"https://secwatch.observer/filing/0001728117-26-000101.md","text":"https://secwatch.observer/filing/0001728117-26-000101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000101/0001728117-26-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000101/goss-20260916.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-16T20:07:31.841812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}